Uncategorized
Editor’s pick: Dispatch Biotherapeutics
Nature Biotechnology, Published online: 18 August 2026; doi:10.1038/s41587-026-03293-z
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Dispatch Bio delivers antigens to solid tumors for CAR T immunotherapy.